在III阶段黑色素瘤中,新辅助性内损伤向免疫细胞因子 (daromun)
K C Kähler1, J C Hassel2, M Ziemer3
1University Hospital Schleswig-Holstein, Campus Kiel, Kiel, Germany.
概括
与前期手术相比,新辅助药达罗蒙在III期黑色素瘤患者中显著改善了无复发的生存率. 这种免疫细胞因子治疗为晚期黑色素瘤提供了一个新的选择,具有可控的副作用.
科学领域:
- 在瘤学瘤学.
- 免疫治疗是一种免疫疗法.
- 黑色素瘤研究 黑色素瘤研究
背景情况:
- 第三阶段试验调查了达罗蒙,这是L19IL2和L19TNF纤维素菌素向免疫细胞因子的组合.
- 专注于临床检测到的IIIB/C阶段黑色素瘤 (AJCC版本7).
研究的目的:
- 评估达罗蒙作为局部晚期黑色素瘤的新辅助治疗方法.
- 主要终点:没有复发的生存率 (RFS).
主要方法:
- 随机试验比较新辅助达罗蒙 (4周) 之后的手术和前期手术.
- 患者每周接受内溶性达罗蒙或立即接受手术;允许辅助治疗.
- 无复发生存期定义为完全切除后疾病复发或死亡的时间.
主要成果:
- 246名患者随机选择;74%的患者先前接受过手术,35%的患者先前接受过全身治疗.
- 新辅助达罗蒙组 (n=122) 的RFS中位数显著长 (16.7个月) 与前期手术 (n=124,6.8个月) 相比.
- 在新辅助手臂中,远程复发风险降低了40%;等级≥3的TRAE为27.1%vs6.7%.
结论:
- 新辅助剂达罗蒙在局部晚期黑色素瘤患者中显著改善了RFS.
- 与治疗相关的不良事件是暂时的,可以控制的.
- 达罗蒙代表了治疗III期黑色素瘤的新疗法,包括复发病例.
相关概念视频
01:27Tumor Immunotherapy
665
Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.
665
02:57Targeted Cancer Therapies
7.8K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
There are several types of targeted therapies against...
7.8K